Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact

Research output: Journal contributionsScientific review articlesResearch

Standard

Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact. / Vidaurre, Rodrigo; Bramke, Irene; Puhlmann, Neele et al.
In: Drug Discovery Today, Vol. 29, No. 7, 104022, 01.07.2024.

Research output: Journal contributionsScientific review articlesResearch

Harvard

Vidaurre, R, Bramke, I, Puhlmann, N, Owen, SF, Angst, D, Moermond, C, Venhuis, B, Lombardo, A, Kümmerer, K, Sikanen, T, Ryan, J, Häner, A, Janer, G, Roggo, S & Perkins, AN 2024, 'Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact', Drug Discovery Today, vol. 29, no. 7, 104022. https://doi.org/10.1016/j.drudis.2024.104022

APA

Vidaurre, R., Bramke, I., Puhlmann, N., Owen, S. F., Angst, D., Moermond, C., Venhuis, B., Lombardo, A., Kümmerer, K., Sikanen, T., Ryan, J., Häner, A., Janer, G., Roggo, S., & Perkins, A. N. (2024). Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact. Drug Discovery Today, 29(7), Article 104022. https://doi.org/10.1016/j.drudis.2024.104022

Vancouver

Vidaurre R, Bramke I, Puhlmann N, Owen SF, Angst D, Moermond C et al. Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact. Drug Discovery Today. 2024 Jul 1;29(7):104022. doi: 10.1016/j.drudis.2024.104022

Bibtex

@article{66477f530c28402cbbf566209d2febca,
title = "Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact",
abstract = "Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the {\textquoteleft}benign-by-design{\textquoteright} approach, which encourages the development of environmentally friendly APIs that are also safe and efficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that influence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that benefit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.",
keywords = "bioaccumulation, chemical mobility, ecotoxicity, environmentally benign, human health, persistence, safe and sustainable by design SSbD, Chemistry",
author = "Rodrigo Vidaurre and Irene Bramke and Neele Puhlmann and Owen, {Stewart F.} and Daniela Angst and Caroline Moermond and Bastiaan Venhuis and Anna Lombardo and Klaus K{\"u}mmerer and Tiina Sikanen and Jim Ryan and Andreas H{\"a}ner and Gemma Janer and Silvio Roggo and Perkins, {Alison Nimrod}",
note = "Publisher Copyright: {\textcopyright} 2024 The Authors",
year = "2024",
month = jul,
day = "1",
doi = "10.1016/j.drudis.2024.104022",
language = "English",
volume = "29",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Ltd",
number = "7",

}

RIS

TY - JOUR

T1 - Design of greener drugs

T2 - aligning parameters in pharmaceutical R&D and drivers for environmental impact

AU - Vidaurre, Rodrigo

AU - Bramke, Irene

AU - Puhlmann, Neele

AU - Owen, Stewart F.

AU - Angst, Daniela

AU - Moermond, Caroline

AU - Venhuis, Bastiaan

AU - Lombardo, Anna

AU - Kümmerer, Klaus

AU - Sikanen, Tiina

AU - Ryan, Jim

AU - Häner, Andreas

AU - Janer, Gemma

AU - Roggo, Silvio

AU - Perkins, Alison Nimrod

N1 - Publisher Copyright: © 2024 The Authors

PY - 2024/7/1

Y1 - 2024/7/1

N2 - Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the ‘benign-by-design’ approach, which encourages the development of environmentally friendly APIs that are also safe and efficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that influence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that benefit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.

AB - Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the ‘benign-by-design’ approach, which encourages the development of environmentally friendly APIs that are also safe and efficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that influence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that benefit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.

KW - bioaccumulation

KW - chemical mobility

KW - ecotoxicity

KW - environmentally benign

KW - human health

KW - persistence

KW - safe and sustainable by design SSbD

KW - Chemistry

UR - http://www.scopus.com/inward/record.url?scp=85193784874&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/04784453-329a-31e7-88eb-1401da7c022f/

U2 - 10.1016/j.drudis.2024.104022

DO - 10.1016/j.drudis.2024.104022

M3 - Scientific review articles

C2 - 38750927

AN - SCOPUS:85193784874

VL - 29

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 7

M1 - 104022

ER -